Harrow Provides Select Preliminary Q2 2023 Financial Guidance; Sees Q2 Revenue In Excess Of $31M Vs 29.2M Est.
Portfolio Pulse from Benzinga Newsdesk
Harrow (NASDAQ:HROW), a U.S. eyecare pharmaceutical company, has provided preliminary Q2 2023 financial guidance. The company expects revenues to exceed $31 million, compared to $23.3 million in Q2 2022. Adjusted EBITDA is also expected to exceed $9.3 million. Full financial results will be released on August 9, 2023.
July 18, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow's Q2 2023 revenue and EBITDA projections exceed estimates, indicating strong financial performance. This could positively impact the company's stock price.
Harrow's projected increase in revenue and EBITDA for Q2 2023 suggests the company is performing well financially. This positive financial performance is likely to increase investor confidence, potentially leading to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100